Juno Therapeutics Sets Terms for Possible $153M IPO
December 10, 2014
Juno Therapeutics, which has raised over $300 million in VC in the past 12 months, has set terms for its upcoming IPO. The biotech plans to price shares within a range of $15 to $18 and list on the NASDAQ under the symbol JUNO; pricing at the range midpoint would raise about $153 million in the offering and bring Juno an initial market cap of $1.26 billion. The company last raised $134 million in August at a $953 million valuation. Backers include Crestline Management (34.75% pre-IPO stake) and ARCH Venture Partners (15.17%).